Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06493032 · ClinicalTrials.gov registry record · NA

The Use of Body Surface Gastric Mapping in Assessing the Clinical Success of G-POEM

A NA study of Gastroparesis, sponsored by Indiana University.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT06493032: Recruiting NA study of Gastroparesis, sponsored by Indiana University.

NCT06493032 is a NA study of Gastroparesis that is actively recruiting participants, run by Indiana University. The registered enrollment target is 20 participants, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06493032, a NA study of Gastroparesis, is actively recruiting participants, sponsored by Indiana University.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate whether or not the investigators can utilize Body Surface Gastric Mapping to determine who would best benefit to receive G-POEM procedure and how Body Surface Gastric Mapping can be utilized with patients who have gastroparesis symptoms. the investigators may also be able to find more ways how Body Surface Gastric Mapping testing can benefit patients with gastroparesis and/or G-POEM procedure.

Primary Outcome

A measure of the concentration of amplitude in the gastric frequency band over time (between 0 and 1), which characterizes the rhythmic stability of the recorded gastric activity; also adjusted for BMI.

Conditions Studied

Interventions

  • DEVICE Gastric Alimetry System

Study Locations (1)

Indiana

  • Indiana University Health University Hospital - Indianapolis

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-11-07
Est. Completion 2026-06-01
Phase NA
Indiana University

890 total trials

What NCT06493032 shows while recruiting

NCT06493032 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Gastroparesis appearing as the primary indexed condition, and to 1 intervention - of which Gastric Alimetry System is the first listed.

NCT06493032 reports a single indexed study location in Indiana.

Frequently Asked Questions

What is clinical trial NCT06493032 about?

NCT06493032 is a clinical study titled "The Use of Body Surface Gastric Mapping in Assessing the Clinical Success of G-POEM". The purpose of this study is to investigate whether or not the investigators can utilize Body Surface Gastric Mapping to determine who would best benefit to receive G-POEM procedure and how Body Surface Gastric Mapping can be utilized with patients who have gastroparesis symptoms. the investigators ...

What is the current status of trial NCT06493032?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-11-07. Estimated completion is 2026-06-01.

What conditions does trial NCT06493032 study?

This clinical trial studies the following conditions: Gastroparesis.

What interventions are being tested in trial NCT06493032?

The interventions under investigation include: Gastric Alimetry System (DEVICE).

Who is sponsoring clinical trial NCT06493032?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06493032 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastroparesis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06493032's enrollment target sits among peer trials

20 34th of 44 higher than 9 of 44 other Gastroparesis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gastroparesis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06493032, the US trial registry maintained by the National Library of Medicine. NCT06493032 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.